Abstract
The aim of the present study was to evaluate the prevalence of anti-cyclic citrullinated peptide (CCP) antibodies in patients with Down’s syndrome (DS) previously tested for IgM rheumatoid factor (RF) and to correlate the results with clinical findings. Eighty-eight patients with DS previously tested for IgM-RF were divided into two groups matched for sex and age. Group A consists of 42 RF positive patients and group B of 44 RF negative patients. The presence of anti-CCP antibody was determined using a second-generation enzyme-linked immunosorbent assay. A total of 52.3% (45/86) of DS patients were positive for anti-CCP antibodies. Twenty-four patients (57.1%) of the RF positive group and 21 (47.7%) of the RF negative group presented anti-CCP circulating antibodies. The concordance between both tests was 54.6%. None of the patients had clinical evidence of rheumatoid arthritis or juvenile idiopathic arthritis. Although a high prevalence of anti-CCP antibodies was observed in DS patients, no association has been found presently with clinical disease. Careful follow-up of these patients will be necessary to clarify the real significance of these findings.
Similar content being viewed by others
References
National Birth Defects Prevention Network (2003) Birth defects surveillance data from selected states, 1996–2000. Birth Defects Res A Clin Mol Teratol 67:729–818
Leonard S, Bower C, Petterson B, Leonard H (2000) Survival of infants born with Down’s syndrome 1980–96. Paediatr Perinat Epidemiol 14:163–171
Pueschel SM, Anneren G, Durlach R et al (1995) Guidelines for optimal care of persons with Down syndrome. Acta Paediatr 84:823–827
Ugazio AG, Maccario R, Notarangelo LD, Burgio GR (1990) Immunology of Down syndrome: a review. Am J Med Genet 7:202–212
Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2005) Celiac disease in children and adolescents with Down syndrome. J Pediatr 81(5):373–376
Nisihara RM, Kotze LM, Utiyama SR, Oliveira NP, Fielder PT, Messias-Reason IT (2006) Alterations of TSH in Down syndrome patients: a hard interpretation. Rev Med Lab 46:333–337
Anwar AJ, Walker JD, Frier BM (1998) Type-1 diabetes mellitus and Down’s syndrome: prevalence, management and diabetic complications. Diabet Med 15:160–163
Goldacre MJ, Wotton CJ, Seagroatt V, Yeats D (2004) Cancers and immune related diseases associated with Down’s syndrome: a record linkage study. Arch Dis Child 89:1014–1017
Padmakumar B, Evans Jones LG, Sills JA (2002) Is arthritis more common in children with Down syndrome? Rheumatology 41:1191–1193
Yancey C, Zmijewski C, Athreya BH, Doughty RA (1984) Arthropathy of Downs’ syndrome. Arthritis Rheum 27:929–934
Olson JC, Bender JC, Levinson JE, Oestreich A, Loveli D (1990) Arthropathy of Down syndrome. Pediatrics 86:931–936
Kinnel HG (1984) Arthritis in Down’s syndrome. Br J Radiol 54:1167
Bas S, Genevay S, Meyer O, Gabay C (2003) Anti-cyclic citrullinated peptide antibodies, IgM and IgA rheumatoid factors in the diagnosis and prognosis of rheumatoid arthritis. Rheumatology 42:677–680
Grahane R (1998) Hypermobility syndrome. In: Kilpell JH, Fieppe PA (eds) Rheumatology, 2nd edn. Mosby, London, S8–51.1–51.6
Cuadrado E, Barrena MJ (1996) Immune dysfunction in Down’s syndrome: primary immune deficiency or early senescence of the immune system? Clin Immunol Immunopathol 78:209–214
Jansen AL, van den Horst-Bruisma IE, van Shaardenburg D, Van den Stad RJ, de Konig MH, Dijkmans BA (2002) Rheumatoid factor and antibodies to cyclic citrullinated peptide differentiate rheumatoid arthritis from undifferentiated polyarthritis in patients with early arthritis. J Rheumatol 29:2074–2076
Hingh YC, Vossen PW, Gemen EF, Mulder AB, Hop WC, Brus F, Vries E (2005) Intrinsic abnormalities of lymphocyte counts in children with Down syndrome. J Pediatr 147:744–747
Franciotta D, Verri A, Zardini E, Andreoni L, Amici M, Moratti R, Nespoli L (2006) Interferon γ and interleukin-4 producing T cells in Down’s syndrome. Neurosci Lett 395:67–70
Berglin E, Padyukov L, Sundin U et al (2004) A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA-DRB1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 6:303–308
Day SM, Strauss DJ, Shavelle RM, Reynolds RJ (2005) Mortality and causes of death in persons with Down syndrome in California. Dev Med Child Neurol 47(3):171–176
Ferraro AS, Newkirk MM (1993) Correlative studies of rheumatoid factors and anti-viral antibodies in patients with rheumatoid arthritis. Clin Exp Immunol 92:425–431
Newkirk MM (2002) Rheumatoid factors: host resistance or autoimmunity? Clin Immunol 104:1–13
Posnett DN, Edinger J (1997) When do microbes stimulate rheumatoid factor? J Exp Med 185:1721–1723
Anzilotti C, Merlini G, Pratesi F, Tommasi C, Chimenti D, Migliorini P (2006) Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 33:647–651
Pratesi F, Tommasi C, Anzilotti C, Chimenti D, Migliorini P (2006) Deiminated Epstein–Barr virus nuclear antigen 1 is a target of anti citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum 54:733–741
Ates A, Karaaslan Y, Aksaray S (2007) Predictive value of antibodies to cyclic citrullinated peptide in patients with early arthritis. Clin Rheumatol 26(4):499–504 (May 3)
Agrawal S, Misra R, Aggarwal A (2007) Autoantibodies in rheumatoid arthritis: association with severity of disease in established RA. Clin Rheumatol 26(2):201–204 (Mar 30)
Acknowledgment
This work was supported by a grant from the Araucária Foundation—Paraná. IJMR is a recipient of the Brazilian National Research Council CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) Research Fellowship (200936/2004-2).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Nisihara, R.M., Skare, T.L., Silva, M.B.G. et al. High positivity of anti-CCP antibodies in patients with Down syndrome. Clin Rheumatol 26, 2031–2035 (2007). https://doi.org/10.1007/s10067-007-0606-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0606-1